Gennex Laboratories Management

Management criteria checks 4/4

We currently do not have sufficient information about the CEO.

Key information

Arihant Baid

Chief executive officer

₹3.0m

Total compensation

CEO salary percentage	99.0%
CEO tenure	12yrs
CEO ownership	0.00007%
Management average tenure	9.3yrs
Board average tenure	6.5yrs

Recent management updates

Recent updates

CEO Compensation Analysis

How has Arihant Baid's remuneration changed compared to Gennex Laboratories's earnings?
Date	Total Compensation	Salary	Company Earnings
Dec 31 2023	n/a	n/a	₹107m
Sep 30 2023	n/a	n/a	₹90m
Jun 30 2023	n/a	n/a	₹70m
Mar 31 2023	₹3m	₹3m	₹49m
Dec 31 2022	n/a	n/a	₹40m
Sep 30 2022	n/a	n/a	₹37m
Jun 30 2022	n/a	n/a	₹37m
Mar 31 2022	₹3m	₹3m	₹39m
Dec 31 2021	n/a	n/a	₹44m
Sep 30 2021	n/a	n/a	₹49m
Jun 30 2021	n/a	n/a	₹46m
Mar 31 2021	₹3m	₹3m	₹40m
Dec 31 2020	n/a	n/a	₹28m
Sep 30 2020	n/a	n/a	₹17m
Jun 30 2020	n/a	n/a	₹14m
Mar 31 2020	₹3m	₹3m	₹19m
Dec 31 2019	n/a	n/a	₹20m
Sep 30 2019	n/a	n/a	₹27m
Jun 30 2019	n/a	n/a	₹25m
Mar 31 2019	₹3m	₹3m	₹22m
Dec 31 2018	n/a	n/a	₹16m
Sep 30 2018	n/a	n/a	₹10m
Jun 30 2018	n/a	n/a	₹10m
Mar 31 2018	₹3m	₹2m	₹8m

Compensation vs Market: Arihant's total compensation ($USD36.33K) is about average for companies of similar size in the Indian market ($USD39.49K).

Compensation vs Earnings: Arihant's compensation has been consistent with company performance over the past year.

CEO

Arihant Baid (37 yo)

12yrs

Tenure

₹3,028,800

Compensation

Mr. Arihant Baid has been Managing Director of Gennex Laboratories Limited since March 2011 and serves as its Executive Director since May 18, 2012. Mr. Baid serves as Chairman of Gennex Laboratories Limit...

Leadership Team

Name	Position	Tenure	Compensation	Ownership
Arihant Baid	Chairman & MD	12yrs	₹3.03m	0.000070% ₹ 2.5k
Laxmipat Baid	Chief Financial Officer	9.3yrs	₹1.74m	no data
K. V. L. Bhaswanth	Chief Operating Officer	no data	no data	no data
Dinesh Kejriwal	Company Secretary & Compliance Officer	1.1yrs	no data	no data

9.3yrs

Average Tenure

Experienced Management: 531739's management team is seasoned and experienced (9.3 years average tenure).

Board Members

Name	Position	Tenure	Compensation	Ownership
Arihant Baid	Chairman & MD	12yrs	₹3.03m	0.000070% ₹ 2.5k
Ravinder Yellu	Non-Executive & Independent Director	21.2yrs	₹21.00k	no data
Sadhana Bhansali	Non-Executive & Independent –Women Director	9.7yrs	₹12.00k	no data
Amudala Sreeramulu Rao	Non-Executive & Independent Director	3.4yrs	no data	no data
Avasarala Ranga Pantulu	Non-Executive & Non-Independent Director	3.4yrs	no data	no data
S. Ch. Rao	Additional Non- Executive Non Independent Director	less than a year	no data	no data

6.5yrs

Average Tenure

56yo

Average Age

Experienced Board: 531739's board of directors are considered experienced (6.5 years average tenure).

Gennex Laboratories Management

Management criteria checks 4/4

Key information

Recent management updates

Gennex Laboratories Limited Announces Resignation of Tiruvarur Muralidharan Gopalakrishnan as Whole Time Director

Insufficient new directors

Gennex Laboratories Limited, Annual General Meeting, Sep 30, 2023

Gennex Laboratories Limited Announces Rajesh Vankadara to Resign as Company Secretary & Compliance Officer Effect from February 26, 2023

Gennex Laboratories Limited Appoints A S Nageswar Rao as Additional Director

Gennex Laboratories Limited Announces Resignation of Vinod Choraria as an Independent Director

Recent updates

Investor sentiment improves as stock rises 20%

New minor risk - Share price stability

Investor sentiment deteriorates as stock falls 20%

Third quarter 2024 earnings released: EPS: ₹0.16 (vs ₹0.067 in 3Q 2023)

Gennex Laboratories Limited to Report Q3, 2024 Results on Feb 14, 2024

Gennex Laboratories Limited Announces Resignation of Tiruvarur Muralidharan Gopalakrishnan as Whole Time Director

Gennex Laboratories Limited announced that it has received INR 794.695 million in funding from Premier Fiscal Services Pvt Ltd, Vidya Tradecon Pvt. Ltd., Vivaya Enterprises Private Limited, Jms Mines & Minerals Pvt Ltd

New minor risk - Shareholder dilution

Investor sentiment improves as stock rises 17%

Insufficient new directors

Gennex Laboratories Limited announced that it expects to receive INR 966.125 million in funding from Premier Fiscal Services Pvt Ltd

Second quarter 2024 earnings released: EPS: ₹0.17 (vs ₹0.083 in 2Q 2023)

Investor sentiment improves as stock rises 15%

Gennex Laboratories Limited to Report Q2, 2024 Results on Nov 14, 2023

Investor sentiment deteriorates as stock falls 16%

New major risk - Share price stability

Investor sentiment improves as stock rises 19%

Gennex Laboratories Limited, Annual General Meeting, Sep 30, 2023

First quarter 2024 earnings released: EPS: ₹0.16 (vs ₹0.06 in 1Q 2023)

Gennex Laboratories Limited to Report Q1, 2024 Results on Aug 14, 2023

Investor sentiment improves as stock rises 25%

New minor risk - Share price stability

Full year 2023 earnings released: EPS: ₹0.32 (vs ₹0.31 in FY 2022)

Investor sentiment improves as stock rises 15%

Third quarter 2023 earnings released: EPS: ₹0.067 (vs ₹0.062 in 3Q 2022)

Gennex Laboratories Limited Announces Rajesh Vankadara to Resign as Company Secretary & Compliance Officer Effect from February 26, 2023

Investor sentiment improved over the past week

Second quarter 2023 earnings released: EPS: ₹0.083 (vs ₹0.09 in 2Q 2022)

Now 20% undervalued after recent price drop

Gennex Laboratories Limited to Report Q3, 2023 Results on Feb 14, 2023

Gennex Laboratories Limited to Report Q1, 2023 Results on Aug 12, 2022

Gennex Laboratories Limited Receives New 2 Licenses to Manufacture Drugs for Purposes of Examination, Test or Analysis from the Drug Control Administration , Government of Telangana

Full year 2022 earnings released: EPS: ₹0.33 (vs ₹0.32 in FY 2021)

Investor sentiment deteriorated over the past week

Third quarter 2022 earnings: Revenues and EPS in line with analyst expectations

Investor sentiment improved over the past week

Investor sentiment improved over the past week

Investor sentiment improved over the past week

Investor sentiment deteriorated over the past week

First quarter 2022 earnings released: EPS ₹0.075 (vs ₹0.029 in 1Q 2021)

Investor sentiment improved over the past week

Investor sentiment improved over the past week

Investor sentiment improved over the past week

Investor sentiment improved over the past week

Investor sentiment improved over the past week

Investor sentiment deteriorated over the past week

Third quarter 2021 earnings released: EPS ₹0.097 (vs ₹0.015 in 3Q 2020)

Gennex Laboratories Limited to Report Q3, 2021 Results on Feb 13, 2021

Investor sentiment improved over the past week

New 90-day high: ₹5.62

New 90-day high: ₹4.94

Gennex Laboratories Limited Appoints A S Nageswar Rao as Additional Director

Market bids up stock over the past week

Market bids up stock over the past week

Gennex Laboratories Limited Announces Resignation of Vinod Choraria as an Independent Director

New 90-day low: ₹3.54

Gennex Laboratories Limited to Report Q2, 2021 Results on Nov 12, 2020

New 90-day low: ₹3.66

New 90-day low: ₹3.98

First quarter earnings released

Full year earnings released - EPS ₹0.15

Gennex Laboratories Limited to Report Q1, 2021 Results on Sep 15, 2020

Full year earnings released - EPS ₹0.15

Gennex Laboratories Limited to Report Q4, 2020 Results on Jul 30, 2020

CEO Compensation Analysis

CEO

Tenure

Compensation

Leadership Team